Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Simple furosemide test may predict kidney decline in ICU

NCT ID NCT06765031

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Aug 06, 2026 · Updated 3 times

Summary

This study tests whether a furosemide stress test can predict if acute kidney injury will get worse in ICU patients. Researchers will give furosemide to 140 patients and measure urine output over 2 hours. The goal is to see if the test can identify who will need dialysis, helping doctors make faster decisions.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
furosemide
What this could lead to
If successful, this test could help doctors predict which ICU patients with acute kidney injury will worsen and need dialysis, enabling earlier treatment decisions.
What could go wrong
This is a small, early-stage study (140 participants) testing a diagnostic tool, not a treatment. The test may not accurately predict outcomes in all patients, and results may not apply to broader populations.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

121 people

The number who actually took part.

Started

Nov 2024

Finished

Mar 2026

Lead sponsor

A government agency

The lead sponsor is a government body.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Those who meet KDIGO AKI stage 1 and stage 2 criteria in the first 24 hours 2. Those with sufficient fluid volume (CVP≥6 cmH20) 3. Female and male patients over the age of 18 will be included in the study Exclusion Criteria: 1. Pregnant patients 2. Hospitalization due to intoxication 3. Liver or kidney transplant 4. Glomerular filtration rate below 30 ml/min/1.73m2 5. Active bleeding 6. Patients with obstructive uropathy 7. Patients in need of urgent RRT (K≥6.6 meq/L, pH\<7.15, pulmonary edema due to fluid overload, uremic complications) 8. Patients evaluated as KDIGO AKI stage 3 9. Patients who have received RRT in the last 30 days 10. Patients with CKD diagnosis 11. Patients with pulmonary embolism 12. Hypoalbuminemia≥2.5 g/dl, 13. Patients receiving cephalosporin treatment will be excluded from the sample.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Akut kidney injury are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Gulhane Training and Research Hospital

    Ankara, keçiören, 06010, Turkey (Türkiye)

More trials for these conditions

Other studies related to the condition(s) this trial covers.